You are here: Industry Insights > CDSCO

News List

CDSCO asks drug controllers to take measures against black marketing of remdesivir expresspharma
July 08, 2020
Reportedly, the drug is being sold at exorbitant prices ranging between Rs 15,000 to Rs 60,000.
Mylan gets approval to make and market remdesivir expresspharma
July 03, 2020
Jubilant, BDR and Dr Reddy's Labs have also awaiting permission from CDSCO to manufacture and market the drug in India and are still awaiting due permission.
CDSCO asks industry to submit suggestions on doping drug labels expresspharma
June 28, 2020
The Drugs Technical Advisory Board will be reviewing the matter and preparing draft guidelines.
CDSCO to inspect BDR Pharma’s formulation facility, submit report in seven days expresspharma
June 22, 2020
It is part of fast tracking manufacturing and marketing applications of remdesivir, informs CDSCO.
Centre clarifies reasons for delay in approvals for remdesivir expresspharma
June 16, 2020
Informs that it is awaiting data on some crucial parameters from companies that have applied for manufacturing and marketing approvals.
Gilead seeks marketing authorisation from CDSCO for remdesivir expresspharma
June 01, 2020
The medicine has been issued EUA by the US FDA to treat hospitalised coronavirus patients.
CDSCO issues recommendations to lift export restrictions on paracetamol APIs expresspharma
May 18, 2020
The letter states that six major manufacturers may be allowed to export up to 50 per cent of their monthly operating capacity in a given month subject to release of a similar quantity for domestic purpose.
CDSCO to assess issues in the procurement and prices of APIs expresspharma
May 06, 2020
Reportedly, prices of APIs for paracetamol has increased exponentially from approximately Rs 250 per kg to Rs 425 per kg in the last three months.
CDSCO extends WHO-GMP/CoPP validity by six months expresspharma
May 04, 2020
The validities of WHO GMP/CoPP expiring between March to August 2020 will be extended by six months from the date of expiry of the certificate as per WHO GMP certification guidelines.
CDSCO anticipates low inventory of cardiac and anti-diabetic medicines, writes to all pharma associations expresspharma
April 27, 2020
The National Pharmaceutical Pricing Authority has requested the CDSCO to provide the details of manufacture of cardiac and anti-diabetic drugs especially in respect of insulin, aspirin and atorvastatin.

Previous page 1 2 3 4 Next page